Last reviewed · How we verify
warfarin accordingly INR value
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) to reduce thrombus formation and is dosed according to INR (International Normalized Ratio) monitoring.
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) to reduce thrombus formation and is dosed according to INR (International Normalized Ratio) monitoring. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) treatment and prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | warfarin accordingly INR value |
|---|---|
| Also known as | warfarin |
| Sponsor | Azienda Ospedaliera Universitaria Policlinico |
| Drug class | Vitamin K antagonist (oral anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin acts as a vitamin K antagonist, blocking the synthesis of vitamin K-dependent coagulation factors in the liver. The INR is monitored to ensure therapeutic anticoagulation (typically 2–3 for most indications) while minimizing bleeding risk. Dosing is adjusted based on INR values to maintain the target range.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (DVT/PE) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Nausea
- Alopecia
Key clinical trials
- Prospective Trial of a Validated Algorithm for Warfarin Dosing (NA)
- Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |